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Abstract
We present a computational method for the reaction-based de novo design of drug-like molecules. The software DOGS
(Design of Genuine Structures) features a ligand-based strategy for automated ‘in silico’ assembly of potentially novel
bioactive compounds. The quality of the designed compounds is assessed by a graph kernel method measuring their
similarity to known bioactive reference ligands in terms of structural and pharmacophoric features. We implemented a
deterministic compound construction procedure that explicitly considers compound synthesizability, based on a
compilation of 25’144 readily available synthetic building blocks and 58 established reaction principles. This enables the
software to suggest a synthesis route for each designed compound. Two prospective case studies are presented together
with details on the algorithm and its implementation. De novo designed ligand candidates for the human histamine H4
receptor and c-secretase were synthesized as suggested by the software. The computational approach proved to be
suitable for scaffold-hopping from known ligands to novel chemotypes, and for generating bioactive molecules with drug-
like properties.
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Introduction
De novo design aims at generating new chemical entities with
drug-like properties and desired biological activities in a directed
fashion [1,2]. This goal corresponds to the major task of the early
drug discovery process and comprises a considerable fraction of
the effort spent by pharmaceutical companies and academic
groups in order to develop new treatments for diseases. De novo
design is complementary to high-throughput screening in its
approach to find innovative entry points for drug development [3].
Instead of searching for bioactive molecules in large collections
of physically available screening compounds, de novo design
‘invents’ chemical structures from scratch by assembling mole-
cular fragments. Computer-assisted approaches to de novo design
automate this process by generating hypothetical candidate
structures in silico. Although related areas of computer-aided drug
development (e.g. virtual screening, quantitative structure-activity
relationship modeling) have gained substantial attention in terms
of publication numbers, de novo design has witnessed a constant
evolution ever since the first computational methods have emerged
in the late 1980s [2]. A number of reviews on this topic have been
published recently, providing a comprehensive overview of the
field [1–4].
Most of the approaches to de novo design attempt to mimic the
work of a medicinal chemist: molecules are synthesized (virtually
assembled from fragments), tested for their biological activity
(computationally evaluated by a scoring function), and the insight
gained serves as the basis for the next round of compound
generation (optimization). De novo design methods differ in the way
they search for, assemble, and score the generated molecules. For
example, scoring can either be performed by computing some
similarity index of candidate compounds and known reference
ligands (ligand-based approach) or based on the three-dimensional
(3D) structure of a ligand-binding cavity (receptor-based approach).
Irrespective of the particular technique used, automated de novo
design has always been confronted with the issue of synthetic
accessibility [1,5]. It may be argued that this is one of the main
reasons why de novo design software has only rarely been subjected
to practical evaluation [3]. An overview of successful de novo design
studies is provided in a recent review article by Kutchukian and
Shakhnovich [4].
Only a small fraction of all molecules amenable to virtual
construction can in fact be synthesized in a reasonable time frame
and with acceptable effort. De novo design programs tackle this
issue by employing rules to guide the assembly process. Such rules
attempt to reflect chemical knowledge and thereby avoid the
formation of implausible or unstable structures. For example, some
assembly approaches prevent connections between certain atom
types, and finally the formation of unwanted substructures [6,7].
Other strategies employ chemistry-driven retrosynthetic rules
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example of this kind of rule set is the RECAP [8] (retrosynthetic
combinatorial analysis procedure), which is also used by some de
novo design tools [9–12]. The software SYNOPSIS [13] follows a
conceptually even more elaborate approach by connecting
available molecular building blocks using a set of known chemical
reactions. This enables the software to suggest reasonable synthesis
pathways along with each final compound.
Here, we present a new approach to computer-assisted de novo
design of ligand candidate structures, and describe its implemen-
tation in the software tool DOGS (Design Of Genuine Structures).
DOGS represents a medicinal chemistry-inspired method for the
de novo design of drug-like compounds, placing special emphasis on
the synthesizability of the designed molecules. The software not
only suggests new compounds, but also provides at least one
motivated, hypothetical synthesis pathway per ligand candidate
structure. The assembly process is based on available molecular
building blocks and a set of established reaction principles. This
strategy forces the program to follow construction pathways that
represent direct blueprints of possible synthesis routes. The
synthesis pathways generated and output by the software include
vendor catalog identifiers of the building blocks and references to
the underlying synthesis protocols.
DOGS grows new molecules in a deterministic and stepwise
process: in each step, complete enumeration of a subspace of all
possible solutions is performed. Following a greedy strategy, top-
scoring intermediate products are submitted to subsequent
growing steps. The quality of designed (intermediate) products is
assessed by a ligand-based scoring scheme. Similarity to a
reference ligand is computed by a graph kernel method. Two
different graph representations of molecules (molecular graph and
reduced graph) have been implemented to allow for different levels of
abstraction from the two-dimensional molecular structure.
In a recently published work, we have successfully applied
DOGS in a first prospective study to designing a selective inhibitor
of human Polo-like kinase 1 (Plk1) in its inactive (DFG-out
activation-loop) conformation [14]. One of the compounds
suggested by DOGS was selected for synthesis based on a series
of post-design analyses and human inspection. Following the
proposed synthesis route, the compound was accessible and found
to have the desired biological effect and selectivity profile in vitro.
The Plk1 study focused on the practical use case and only pro-
vides a brief description of the method. Here, we disclose the
algorithmic details and give a full description of the implemen-
tation. We present a theoretical evaluation of the software with
respect to general properties of designed compounds, and show its
ability to suggest well-motivated bioisosteric replacements. We also
present two new prospective case studies: Three compounds
designed by DOGS (two suggested as modulators of c-secretase
and one as an antagonist of human histamine H4 receptor) were
selected for chemical synthesis and subsequently tested for in vitro
bioactivity. In all cases, the proposed synthesis plan was readily
pursuable as suggested by the software.
Methods
Library of Chemical Reactions
The DOGS algorithm builds up new candidate structures
by mimicking a multi-step synthesis pathway. This strategy is
supposed to deliver a direct blueprint for the actual synthesis of
proposed candidate structures. For this approach, established
reaction protocols need to be formalized in order to make them
processable by a computer. Reactions were encoded using the
formal language Reaction-MQL [15]. The specification of a
reaction as a Reaction-MQL expression consists of a reactant side
on the left and a product side on the right. A reactant is specified
only by the substructure that is directly involved or essential for the
reaction (reaction center) in order to make the description applicable
to a broad spectrum of reactants with variable substituent groups
(R-groups). The product is described by bond rearrangements
caused by the reaction (Figure 1). All Reaction-MQL represen-
tations used in this work feature reactants with variable R-groups
to keep them as generic as possible. Catalysts and invariant
reactants are not denominated in the reaction expressions.
DOGS implements 83 reactions (termed coupling reactions in the
following), 58 of which are unique and 25 represent either charge
variations (reactants) or regioisomer variations (products) of one of
the unique reactions. The complete list of reactions is provided in
Table S1 in Text S1, supplementary material. Out of the 58
unique reactions, 34 describe ring formations. All reactions require
one or two reactants (referred to as one- or two-component reactions,
respectively) and result in a single product (ARB; A+BRC). In
case a reaction generates regioisomers, it is split into two separate
Reaction-MQL expressions, each describing one of the regioi-
somer products.
Building Block Library for Virtual Synthesis
A subset of the Sigma-Aldrich (Sigma-Aldrich Co., 3050 Spruce
St, St. Louis, MO 63103, USA) catalog containing 56,878
chemical building blocks was downloaded from the ZINC
database [16,17]. These compounds served as a basis for the
Figure 1. Encoding of reactions. Example of a Paal-Knorr pyrrole
reaction encoded as Reaction-MQL expression (top). Reactant substruc-
ture descriptions (left part) are separated by ‘++’. The product (right
part) is separated from the reactants by ‘.. ID ..’ where ID is an
arbitrary identifier of the reaction. A direct structural representation of
the line notation description including atom identifiers is shown in the
center. The conventional structural representation of the reaction
(bottom) denotes variable parts of molecules by R-groups (R
x).
doi:10.1371/journal.pcbi.1002380.g001
Author Summary
The computer program DOGS aims at the automated
generation of new bioactive compounds. Only a single
known reference compound is required to have the
computer come up with suggestions for potentially
isofunctional molecules. A specific feature of the algorithm
is its capability to propose a synthesis plan for each
designed compound, based on a large set of readily
available molecular building blocks and established
reaction protocols. The de novo design software provides
rapid access to tool compounds and starting points for the
development of a lead candidate structure. The manu-
script gives a detailed description of the algorithm.
Theoretical analysis and prospective case studies demon-
strate its ability to propose bioactive, plausible and
chemically accessible compounds.
De novo Design
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preparation protocol.
In the first step, building blocks were standardized, and
unsuitable entries were eliminated. For this purpose, a prepro-
cessing routine was developed and implemented using the software
MOE (version 2009.10; Chemical Computing Group, Suite 910,
1010 Sherbrooke Street West, Montreal, Quebec, Canada):
N Compounds with a molecular mass of less than 30 Da or more
than 300 Da were removed.
N Compounds containing more than four rings were removed.
N Compounds with any element type other than C, N, O, S, P,
F, Cl, Br, I, B, Si, Se were removed.
N Compounds containing more than three fluoride atoms were
removed.
N Compounds featuring atoms with incorrect valences were
removed.
N Compounds containing unwanted substructures were removed
according to the recommendations by Hann et al. [18] (cf.
Figure S1 in Text S1, supplementary material).
N Protonation states and formal charges were set according to
MOE’s washing routine (carboxylic acids were deprotonated;
most of the primary, secondary and tertiary amines were
protonated).
N Duplicate entries were removed.
In the second step, the filtered compound set was subjected to a
collection of preprocessing reactions. A set of 15 functional group
addition (FGA) and functional group interconversion (FGI)
reactions was compiled from the literature and encoded as
Reaction-MQL expressions (for a complete list of preprocessing
reactions see Table S2 in Text S1, supplementary material). FGA
and FGI reactions are supposed to introduce reactive functional
groups to building blocks to make them applicable to coupling
reactions during the virtual compound construction process. Each
time a building block was converted by any of the 15 reactions its
original version was kept, and the converted building block was
added to the library.
The third and final step of the preparation process comprises
the annotation of reactive substructures (i.e. which building block
can act as a reactant for which reaction). In order to be annotated
as a reactant for a reaction, a building block has to match one of
the reactant’s substructure definitions exactly once. Forbidding
the same functional group to be present multiple times is
supposed to avoid unwanted side products or the need for
excessive use of protecting groups in the actual chemical
synthesis. (Please note that in the current version of the software
no additional effort is made to estimate the reactivity of
competing functional groups.) After annotation, building blocks
are stored in a MySQL (Oracle Corporation, 500 Oracle
Parkway, Redwood Shores, CA 94065, USA) database. The
resulting building block library accessible to DOGS contains
25’144 entries.
Construction Algorithm
DOGS generates new molecules by iterative fragment assem-
bly. The design cycle comprises the modification of a current
intermediate product by applying one of the chemical reactions
from the library, i.e. the extension of the intermediate product
(growing step). The product of a design cycle is an intermediate
compound, which is modified in the subsequent iteration. A design
cycle features two steps:
Step 1: Selection of the applied reaction. An
intermediate product Z will typically exhibit more than
one functional group that can be addressed by reactions
from the reaction library. Each of these groups can
potentially serve as an attachment point (AP) to connect
another building block. In order to identify the most
promising AP of Z and the reaction to apply, we used
minimal dummy fragments. A minimal dummy fragment is a
virtual molecule that exclusively features the minimal
structural demands that have to be fulfilled in order to
participate in a certain reaction. This concept is
supposed to estimate the smallest structural changes a
reaction will introduce (Figure 2). A one-component
reaction does not define any minimal dummy fragment.
It can directly be applied to a molecule without the
involvement of a second variable reactant contributing
any atom to the formed product. Thus, structural
changes to Z do not need to be estimated but are
determined by simply applying the reaction. In contrast,
a two-component reaction defines two minimal dummy
fragments.
For extending an intermediate compound Z,t h e
algorithm first detects which of the implemented
reactions can be applied to the attachment points
offered by Z. Each of these reactions is applied to Z
with a complementary minimal dummy fragment,
resulting in a list of dummy products. Here, one dummy
product corresponds to exactly one reaction. By
subsequently scoring the dummy products, DOGS
implicitly scores the corresponding reactions. The
reaction yielding the top-scoring dummy product is
pursued in Step 2. In case more than one top-scoring
reaction is identified all of them are considered in Step 2.
Step 2: Selection of a new building block. In case
Step 1 selected a one-component reaction, Z is directly
modified. Otherwise (two-component reaction), the
reaction is performed using all building blocks from
the library holding the respective reactive substructure
(Figure 2). Each generated product is evaluated
according to the scoring function. The top-scoring
compound is selected and represents the extended
intermediate product for the next design cycle. If more
than one intermediate product is scored favorable, all of
them will be considered for the next round. In order to
restrict the number of molecules generated during each
step and to prevent combinatorial explosion, the
maximal number of intermediate products proceeding
to the next extension round was limited to 10.
The algorithm evaluates every building block processed by the
dummy reaction steps according to the scoring function. Each of
the n top-scoring building blocks is considered as a potential
starting point for a distinct synthesis pathway. Parameter n is
defined by the user and controls the number of compounds
resulting from a design run.
Once the design of a new compound based on a selected
starting building block is initiated it will be continued until one of
two stop criteria is fulfilled.
The first stop criterion controls the molecular mass of the
designed compounds. The reference compound’s mass (100%)
defines a relative lower (70%) and upper (130%) bound. A
constructed molecule has to exhibit a molecular mass lying within
these boundaries to be accepted as a valid final product. During
the design of a new molecule the algorithm continuously adds
De novo Design
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the lower mass boundary. Up to this step the extension of the
intermediate product is accepted even if its score value decreases.
Once the molecular mass of the intermediate product exceeds the
lower mass boundary, the algorithm will only accept a subsequent
extension step if it leads to an improved score. In case the addition
of a building block leads to a lower score or causes the molecular
mass to exceed the upper mass limit, the last reaction step is
neglected and the previous intermediate product is added to the
list of final products.
The second stop criterion is supposed to truncate the number
of synthesis steps to keep proposed synthesis pathways short. A
pathway is interrupted regardless of any other condition when it
exceeds a user-defined maximal number of synthesis steps (set to a
value of four steps in all runs presented in this study). In this case,
the intermediate product formed by the last valid reaction step is
added to the list of final products, and a new synthesis pathway is
initiated based on another starting building block. Figure 3
presents the core of the DOGS compound design algorithm.
DOGS tries to construct at least one compound starting from
each of the n building blocks considered to be the most promising
starting points. It is possible that an initiated synthesis path does
not produce a final product. This happens when the growing
intermediate product does not offer an attachment point to add
another building block before it exceeds the minimal mass limit. In
such a case, DOGS automatically skips this particular synthesis
and increments n by 1 to guarantee that at least n final products
are generated. Typically, a run will result in more than n final
products because synthesis pathways can split if more than one
top-scoring intermediate product is generated. In this case,
multiple final products will be designed on the basis of a starting
building block. All steps of the design algorithm are deterministic,
i.e. two runs of DOGS with identical parameters will deliver
identical results.
Scoring Function
The scoring function assesses the quality of a molecule with
respect to the design objective. Products of each stage of a virtual
synthesis pathway (dummy products, intermediate products, final
products) are evaluated by the same scoring function. DOGS
employs a two-dimensional (2D) graph kernel method (ISOAK
[19]) for scoring the designed molecules. The graph kernel was
originally developed for similarity searching in virtual screening of
compound databases, where it has been applied successfully [20].
ISOAK can be readily employed as a scoring function for ligand-
based de novo design, where, like in virtual screening, similarity to a
given reference ligand (a known bioactive compound) forms the
key objective.
Briefly, ISOAK computes similarity values for two molecules
based on their 2D topological structures. Molecules are interpreted
as graphs, where atoms are represented as vertices and covalent
bonds as edges between vertices (molecular graph). Hydrogen atoms
are removed from the graph. Vertices are ‘colored’ by one of eight
pharmacophoric feature types assigned to the corresponding
atom (A: hydrogen-bond acceptor, D: hydrogen-bond donor, E:
hydrogen-bond donor & acceptor, P: positive charge, N: negative
charge, R: aromatic, L: lipophilic, 0: no type; the list of atom type
definitions can be found in Table S3 in Text S1, supplementary
material). A recursive definition of similarity between compared
atoms (‘‘two atoms are similar if their neighbors are similar’’) is
iteratively employed until the process converges. Parameter a
controls the influence of the graph neighborhood, where higher
values increase the impact of the neighborhood. Based on
calculated atom-pair similarities, an optimal assignment of each
atom of the smaller graph to one atom of the larger graph is
computed. The assignment maximizes the sum of atom-pair
similarities, which gives the overall similarity of the compared
molecules. Similarity values are adjusted for compound size by
scaling by the number of non-hydrogen atoms.
Reduced Graph Representation
In addition to the molecular graph described in the previous
section, a reduced graph representation of molecules was implement-
ed as an alternative description of molecules. Reduced graphs only
represent the overall topological arrangement of structural
features. The motivation to use them for de novo design was to
encode molecules in a representation featuring a higher level of
abstraction from the molecular composition and constitution.
Similar to the FeatureTrees [21] approach, the reduced graph
representation employed by DOGS reduces cyclic substructures as
well as clusters of ‘lipophilic’ and ‘no type’ atoms to single vertices
(Figure 4A). In general, each ring that is part of the smallest set of
Figure 2. Two-step procedure of an extension cycle. Step 1 (left) selects the reaction by scoring generated dummy products. In the example,
only two reactions can be applied (Suzuki coupling and amide coupling), and the amide dummy product scores favorable. In Step 2 (right), all
reactants from the building block library exhibiting a suitable amine are added to the growing molecule via amide bond formation. The top-scoring
product represents the extended intermediate product and is selected for the next design cycle.
doi:10.1371/journal.pcbi.1002380.g002
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this rule are fused ring systems with atoms belonging to more than
two rings of the SSSR. In this case, it is not possible to represent
each ring as a single vertex and still obtain a simplified acyclic
graph representation of the molecule. Such ‘amalgamated’ ring
systems are reduced to a single vertex as a whole (Figure 4B). In
order to distinguish the reduced graph representation of two
adjacent rings that are connected by a bond and two fused rings
(rings sharing atoms), the corresponding vertices of reduced graphs
representing the rings are connected by an edge of order one
(‘single bond’) in the former case and two (‘double bond’) in the
latter (Figure 4C).
Vertices of reduced graphs are labeled with bit vectors that store
information about the atoms they represent. These bit vectors
consist of ten bits (one for each of the eight atom types, and two
additional bits standing for ‘ring’ and ‘amalgamated ring system’,
respectively). A vertex bit is set if the corresponding feature is
present in the set of atoms the vertex encodes. Vertices not only
store the bit vector but also the number of atoms they represent.
Accordingly, a benzene substructure would be converted to a
single vertex which is labeled by a bit vector with bits for ‘ring’ and
‘aromatic’ set to 1, and stores an atom count of six. Pyridine would
be encoded in the same way, except for the bit ‘hydrogen-bond
acceptor’ being also set to 1.
Bit vectors (bv) and atom counts (ac) are used to compute the
similarity of two vertices A and B of reduced molecular graphs.
The similarity is computed by multiplying two terms (Eq. 1).
f(acA,acB,bvA,bvB)~sdFactor(acA,acB):Ti(bvA,bvB): ð1Þ
Term 1 (sdFactor) returns a value between 0 and 1 depending on
the difference between the atom count values of compared vertices
(Eq. 2), defined as
sdFactor(acA,acB)~
1 if jacA{acBj~0
0:98 if jacA{acBj~1
0:9 if jacA{acBj~2
0:8 if jacA{acBj~3
0:5 if jacA{acBj~4
0:3 if jacA{acBj~5
0 if jacA{acBjw5
8
> > > > > > > > > > > <
> > > > > > > > > > > :
ð2Þ
Figure 3. Flowchart of the molecule design algorithm. (A) The stop criterion controlling the maximum number of reaction steps is excluded
from the flowchart for simplification. (B) Detailed description of flowchart element B (grey circle). It comprises the key steps taken to extend
intermediate product Z and yield the top-scored intermediate product Z ˇ (=Z grown by an additional fragment) by applying in silico reactions.
doi:10.1371/journal.pcbi.1002380.g003
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3).
Ti(bvA,bvB)~
c
azb{c
, ð3Þ
where c is the number of bits set to 1 in both vectors, a is the
number of bits set to 1 in bvA and b is the number of bits set to 1 in
bvB. Component sdFactor can be seen as a penalty function for atom
count differences modulating the Tanimoto index. In case the
atom count of compared vertices is equal (e.g. two six-membered
rings are compared), fvc reduces to the Tanimoto index. If the
difference between the atom counts exceeds five, fvc will return 0
regardless of the calculated Ti for the bit vectors.
All other components of ISOAK including the edge comparison
are identical to the molecular graph comparison. ISOAK can only
processes graphs with a maximum vertex connectivity of six, i.e. a
vertex of a graph processed by ISOAK must not have more than
six directly connected neighbors. While this will not happen in
molecular graphs (typically, no element that is present in drug-like
molecules will form more than six covalent bonds), such cases can
occur in reduced graphs. For example, 1H-phenalene (Figure 4B)
is represented as a single vertex and offers up to nine positions for
substitution. Molecules containing vertices with more than six
neighbors in their reduced graph representation are excluded from
subsequent steps and discarded.
The molecular representation used in a design run is selected by
the user, i.e. a DOGS run is either based on the molecular graph
or reduced graph scoring scheme.
Implementation
The DOGS software was implemented in the programming
language Java (Oracle Corporation, 500 Oracle Parkway,
Redwood Shores, CA 94065, USA) version 1.6 and uses the
Chemistry Development Kit (CDK, version 1.0.2) [23,24].
Results/Discussion
Theoretical Analysis: Design of Potential Trypsin
Inhibitors
Our initial theoretical analyses of the algorithm were based on
de novo designed compounds originating from ten distinct DOGS
runs. Five trypsin inhibitors served as reference ligands for these
runs (Figure 5). For each reference, a design run based on the
molecular graph representation (a=0.875, default of ISOAK) and
a second run applying the reduced graph representation (a=0.4,
selected based on preliminary empiricism) was performed. The
number of start fragments was set to 200. The ten runs resulted in
a total of 1’767 unique compounds.
Molecular properties. Although successful de novo design
will likely be followed-up by structural optimization of selected
compounds in order to improve their potency and pharmacokinetic
properties, the computer-designed compounds are supposed to
already have drug-like properties in the first place. In order to
assess the drug-likeness of molecules generated by DOGS, violations
of Lipinski’s ‘rule of 5’ [25] were recorded for the 1’767 molecules
using a descriptor implemented in the software MOE. An analysis of
the Lipinski ‘rule’ violations revealed that most of the compounds
(79%) constructed by DOGS violate less than two rules (Figure 6A).
Only 52 proposed molecules (3%) cause three violations. The
distribution of designed compounds mirrors the one of the reference
ligands. A second analysis of the drug-likeness of DOGS designs was
carried out for the same set of designed compounds using an artificial
neural network [26]. This classifier was trained on a set of drugs and
presumed non-drugs to score molecules between 0 (low drug-likeness)
Figure 4. Reduced graph representation. (A) An example of a reduced graph representation. Dashed lines connect atoms or rings of the
molecule (left) with their corresponding vertex of the reduced graph (right). For clarity only some lines are shown. (B) Examples of polycyclic
(‘amalgamated’) substructures translated to a single vertex in the reduced graph. (C) Edges of order two are used to connect fused rings (bottom)i n
order to distinguish the shown cases of neighbored rings in reduced graph representation.
doi:10.1371/journal.pcbi.1002380.g004
Figure 5. Known trypsin inhibitors. Five trypsin inhibitors served as
reference compounds for DOGS design runs (Camostat [45], NAPAMP
[46], Efegatran [47], Patamostat [48,49], UK-156406 [50]).
doi:10.1371/journal.pcbi.1002380.g005
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DOGS 904 (51%) receive a score of 0.8 or higher (Figure 6B). A
considerable number (436) of the DOGS molecules receive a poor
drug-likeness score below 0.1. This can probably be explained by the
fact that one of the reference compounds receives a low drug-likeness
score (Patamostat, score=0.11). Compounds designed to maximize
similarity to this reference can be expected to receive poor drug-
likeness scores as well.
Lipophilicity is considered a relevant physicochemical property
for drug candidate molecules [27]. A common parameter closely
related to lipophilicity is the octanol-water partition coefficient
(logP(o/w)) [28]. One of the Lipinski guidelines states that a
logP(o/w) value greater than five decreases the potential of a
molecule to be absorbed [27]. LogP(o/w) values were calculated
for the five trypsin reference ligands and the molecules designed by
DOGS using the logP(o/w) descriptor implemented in MOE
(Figure 6C). The distribution of calculated logP(o/w) values of
DOGS designs approximates a unimodal distribution centered at
2,logP,3. This is in agreement with the distribution of values
calculated for the reference ligands. Apparently, DOGS is able to
mimic this property of the references in the generated compounds,
although it is not explicitly considered during the design.
It is of critical importance that molecules designed in silico not
only exhibit some desired properties but also are amenable to
chemical synthesis in order to be of any practical value for drug
discovery projects. A molecular descriptor (rsynth) implemented in
the software package MOE estimates the ‘synthesizability’ of
molecules as the fraction of heavy atoms that can be traced back to
starting material fragments resulting from retrosynthetic rules. A
score value of 1 means full coverage of atoms and expected high
synthesizability. The rsynth descriptor was calculated for both
the reference set and the set of de novo designed molecules.
Accordingly, most of the DOGS designs are deemed synthesizable,
as 77% of compounds receive a score greater than 0.9. Most of the
remaining designs receive scores between 0.4 and 0.8. Reference
compound UK-156406 was scored low (rsynth=0.37). A total of
36% (141 of 397) of all DOGS designs scoring below 0.8 originate
from this reference ligand, which exceeds an expected fraction of
Figure 6. Property distributions. Comparison of property distributions between compounds designed by DOGS (left) and the reference
compounds (right). ‘Rule of 5’ violations (A) and logP(o/w) values (C) were calculated using MOE. Dug-likeness scores (B) were computed by a trained
neural network classifier (1=high drug-likeness).
doi:10.1371/journal.pcbi.1002380.g006
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referencesto equal parts.Thismeansthat lowsynthesizabilityscores
are enriched for molecules originating from a reference compound
that is scored unfavorably. This finding points to a positive
correlation between the rsynth score of a reference compound and
rsynth scores of derived DOGS compounds, probably due to the
principle of structural similarity underlying the scoring scheme.
However, a larger number of examples will be needed to support
this hypothesis on a solid statistical basis. For each of the five trypsin
referenceligands,wefoundaconsistenttrend thatdesignrunsbased
onthemoleculargraph representation yieldslightlyhigheraveraged
rsynth scores than the corresponding runs using the reduced graph
representation (cf. Table S4 and Figure S2 in Text S1, supplemen-
tary material). Overall, this preliminary result may be considered a
success of the DOGS approach to generate molecules that are
deemed highly synthesizable.
In summary, the majority of the DOGS designs possesses drug-
like properties and is chemically plausible. Most compounds are
deemed being amenable to chemical synthesis. The proposed
molecules resemble the reference compounds in properties that are
not explicitly considered by the scoring function.
Bioisosteric replacement. Bioisosteric replacement [29] of
functional groups is key to successful de novo design. In order to test
DOGS for its ability to perform bioisosteric replacement, the list of
1’767 potential trypsin ligands designed by the software (resulting
from ten runs based on five trypsin inhibitor references) was
ranked according to the scores assigned by DOGS. The top 200
molecules were analyzed for functional groups that replace side-
chains of the reference compounds addressing the S1 pocket of the
enzyme (guanidinium and benzamidine, Figure 7).
Starting at rank position 78 (compounds on higher ranks exhibit
one of the fragments present in the references), DOGS suggested
eleven different side-chains replacing the reference fragments.
Most of them offer the possibility to interact with the negatively
charged aspartate side-chain of the S1 binding pocket of trypsin by
a positively ionizable nitrogen atom. The terminal urea group and
the two aromatic fragments (pyrimidin-2-amine and pyridin-2-
amine) are exceptions, where the nitrogen will likely not carry a
positive charge. The formation of this salt bridge is a known key
interaction inside the S1 pocket [30]. Although salt bridge
formation is unlikely for these three fragments, they might still
be able to form a hydrogen-bond to the aspartate side-chain. In
fact, both pyrimidin-2-amine and pyridin-2-amine act as S1-
addressing moieties in known trypsin inhibitors (Figure 8). In
addition, the list of proposed side-chains contains an alkyl chain
carrying a terminal nitrogen atom. This fragment resembles the
side-chain of lysine, which is part of the substrates occupying the
S1 pocket during peptide bond cleavage [30].
In summary, DOGS was able to suggest reasonable bioisosters
for parts of the reference ligands addressing the S1 pocket of
trypsin, including experimentally validated examples.
Examples of designed compounds. Two examples selected
from the list of structures proposed by DOGS as potential trypsin
inhibitors are presented in Figure 9. Compounds 1 and 2 were
obtained from design runs based on Efegatran and Camostat.
Compound 1 (originating from the reference ligand Efegatran)
features a central sulfonamide moiety that is not present in
the reference molecule. In this example, DOGS replaced a
substructure of the reference by a structurally different but
presumably isofunctional fragment that is found in other trypsin
inhibitors (for example in NAPAMP and UK-156406, Figure 5).
The guanidinium side-chain of Efegatran was exchanged by the
structural analog 3-methylguanidinium. The overall composition
of functional groups in compound 1 resembles the topological
arrangement in the reference. The synthesis route proposed by
DOGS will probably have to be augmented by the use of
protection groups. For example, the formation of the ester bond in
the last synthesis step can be disturbed by the competing formation
of an amide bond with the primary amine of reactant 2-
aminocyclopentanol. Protection of the amine group could solve
this problem. Note that DOGS currently does not consider
protection groups. Competing side reactions are only addressed by
avoiding multiple occurrences of the same functional group in a
reactant.
Compound 2 was derived using Camostat as reference ligand.
Compared with the former example of molecule 1, computer-
generated molecule 2 is structurally more distinct from its
reference. While the guanidinium group of the reference is
preserved, it is connected to an alkyl chain instead of a phenyl
ring. Alkyl linkers connecting the guanidinium group can also be
found in Efegatran and in the side-chain of arginine, a natural
substrate of the trypsin S1 pocket [30]. An aromatic substructure
distant from the part addressing the S1 pocket is another feature of
compound 2 that can be found in known trypsin ligands as well (cf.
NAPAMP, Figure 5). As the main goal of de novo design is the
generation of isofunctional but structurally novel molecules,
compound 2 might be considered a potential candidate for
further investigations.
Figure 7. Bioisosteric replacement. Side-chains addressing the S1 pocket present in the reference compounds (left) and surrogates suggested by
DOGS found in top-scored 200 designs (right).
doi:10.1371/journal.pcbi.1002380.g007
De novo Design
PLoS Computational Biology | www.ploscompbiol.org 8 February 2012 | Volume 8 | Issue 2 | e1002380Prospective Study 1: c-Secretase
DOGS was employed to propose candidate structures as new
modulators of c-secretase, an aspartic protease that cleaves the
amyloid precursor protein (APP) and generates potentially toxic
amyloid-b (Ab) peptides [31]. Formation and accumulation of
soluble Ab oligomers in the brain is thought to be a primary
pathological event in Alzheimer’s disease [32]. c-Secretase
modulators shift the product ratio of APP processing from the
highly amyloidogenic Ab42 peptides towards shorter Ab frag-
ments with a lower propensity to aggregate like Ab38 [31,33].
Four different reference ligands known to modulate c-secretase
were selected. For each reference compound, two DOGS runs
(molecular graph representation, a=0.875; reduced graph
representation, a=0.4) were performed. The resulting eight
compound lists were visually inspected, and two appealing ligand
candidates 3 and 4 were selected for synthesis (Figure 10).
Synthesis plans were readily traceable as suggested by the
software. One-step reactions yielded the desired products in both
cases. Hence, DOGS demonstrated its ability to come up with
compounds considered as promising candidates by medicinal
chemists and proved to be chemically accessible as suggested (cf.
Figure S3, Figure S4, Protocol S1 and Protocol S2 in Text S1,
supplementary material). Synthesized compounds were tested for
their ability to modulate the c-secretase product spectrum as
previously described [34]. CHO cells with stable overexpression
of human APP and presenilin-1 were treated with increasing
concentrations of 3 and 4. Subsequently, concentrations of secreted
Ab peptides were detected in cell supernatants by sandwich ELISA
using C-terminus specific antibodies that distinguish between Ab38,
Ab40, and Ab42 peptide species [34]. ELISA results indicate
inverse modulation of c-secretase activity (cf. Figure S5 in Text S1,
supplementary material). Compound 3 induced a dose-dependent
increase in Ab42 levels with a concomitant decrease in Ab38 levels.
Similar results were obtained for compound 4. This pattern of
inverse c-secretase modulation has previously been observed, e.g.
with derivatives of the non-steroidal anti-inflammatory drug
indomethacin [35]. Although inverse c-secretase modulation is
not the effect intended for potential treatment of Alzheimer’s
disease, these results clearly show that DOGS is able to design
compounds with pharmacological activity on the macromolecular
target. Compounds 3 and 4 can serve as tool compounds and –
more importantly – as starting points for an optimization of the
pharmacological profile by structural modification.
Prospective Study 2: Human Histamine H4 Receptor
Histamine is a biogenic amine involved in a plethora of
signaling pathways as a messenger. Four subtypes of histamine
receptors (hH1R–hH4R) are known in human. All subtypes
belong to class A (rhodopsin-like) of the G-protein coupled
receptor (GPCR) superfamily [35,36]. Some antagonists of hH1R
and hH2R are approved drugs for the treatment of allergic
reactions and ulcer. Clinical trials of hH3R antagonists for the
Figure 9. Suggested trypsin inhibitors. Compounds 1 and 2 were proposed by the software as potential trypsin inhibitors. Reference ligands
(Efegatran [47], Camostat [45]) and suggested synthesis pathways are presented for both candidate structures.
doi:10.1371/journal.pcbi.1002380.g009
Figure 8. Side-chains addressing the S1 pocket of trypsin.
Known inhibitors of trypsin exhibiting pyrimidin-2-amine [51] (left) and
the pyridin-2-amine [52] (right) side-chains (grey circles). These moieties
were also suggested by DOGS as bioisosters for side-chains of the
reference ligands addressing the S1 pocket of trypsin.
doi:10.1371/journal.pcbi.1002380.g008
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schizophrenia and sleep/wake disorders are currently in progress
[37].
We applied DOGS to provide ideas for new selective
antagonists or inverse agonists of hH4R. For this purpose, two
reference ligands (an inverse agonist and an antagonist) were
employed (Figure 11). For each reference, the molecular graph
representation (a=0.875) as well as the reduced graph represen-
tation (a=0.4) was applied, resulting in a total of four DOGS runs.
Three prioritized designs 5–7 are presented in Figure 11.
N-methylpiperazine is present in both reference compounds.
This moiety is often used as a basic head group in H4 receptor
ligands [38]. The positive charge of basic amines is believed to
form a key interaction to a negatively charged amino acid
side-chain of the protein [39]. While in compound 5 the N-
methylpiperazine moiety is preserved, it is replaced in 6 and 7 by
isofunctional groups. Both represent aliphatic rings with basic
nitrogen atoms, which provide a chance to undergo the charge-
mediated interaction with the receptor. Localization of aromatic
ring systems of the reference compounds is also approximately
kept within the proposed structures.
The attempt to follow the synthesis scheme proposed for
compound 5 was not continued after facing solubility problems of
the aminothiazole building block, which led to extremely poor
yields of the intermediate product. Awkward behavior of reactant
building blocks represents one potential problem of the transition
from in silico to bench synthesis, illustrating the demand of this
endeavor.
Compound 7 was deemed to be of special interest, as it
combines two structural elements that can be found in reported
H4R ligands: an alkylic linker chain with an ether bridge and a
central triazole ring (Figure 12). Notably, both structural elements
are absent from the reference compound. The moderate affinity of
the triazole-carrying ligand 8 (Ki=35mM) [40] may be caused
by a missing hydrogen-bond acceptor in the central part, an
interaction site that is believed to play a role in ligand binding to
H4R [39]. The oxygen atom of the ether bridge present in
designed compound 7 and H4R ligand 9 [41] is able to act as a
Figure 10. Automated design of c-secretase modulators. Compounds 3 and 4 were proposed by DOGS as potential modulators of c-
secretase. Synthesis plans were suggested by the software and successfully pursued. Molecules 3 and 4 originate from distinct runs based on
different reference ligands [53].
doi:10.1371/journal.pcbi.1002380.g010
Figure 11. Automated design of H4 ligands. Compounds 5 and 6 were proposed by DOGS based on an inverse agonist of hH4R [40] (A).
Compound 7 is a design originating from the hH4R antagonist JNJ7777120 [54] (B).
doi:10.1371/journal.pcbi.1002380.g011
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assigns this oxygen to the carbonyl oxygen of the reference, which
also represents a hydrogen-bond acceptor.
In order to test for the hypothesis that a combination of the
features – as found in compound 7 – might lead to hH4R affinity,
compound 7 was selected for synthesis and testing. The synthetic
procedure was realized exactly as suggested by the software
(cf. Figure S6, Protocol S3 in Text S1, supplementary material).
Binding affinity of compound 7 was determined in a competitive
binding assay by measuring displacement of radioactively labeled
[
3H]histamine bound to hH4R [42]. Membrane preparations of
insect Sf9 cells expressing hH4R together with G-protein subunits
Gai2 and Gb1c2 were performed to yield the protein. A similar
assay was used to measure the activity on hH3R (reference ligand:
[
3H]N
a-methylhistamine) [43]. Compound 7 exhibits only very
weak affinity to hH4R. From three measurements, a mean Ki of
4366137 mM was determined. Comparable results were found
for the activity of 7 on the hH3R receptor (Ki=4666209 mM,
averaged over four distinct tests).
A reason for the weak affinity of 7 might be a missing hydrogen-
bond donor in the central part, which has been suggested to play a
role in the interaction of some known H4 ligands with the receptor
[39,44]. In fact, the nitrogen atom of the indole moiety of
reference compound JNJ7777120 can act as a hydrogen-bond
donor. Introduction of a hydrogen-bond donor to the central part
and the exchange of the piperazine head group against N-
methylpiperazine represent comparably small structural changes
to compound 7 and might be considered as first steps to improve
binding affinity.
Additionally, compound 7 was tested against a panel of 30 other
human GPCRs (assays were performed by Cerep, Le bois
l’Eve ˆque, 86600 Celle l’Evescault, France; human GPCRs tested:
A2A,A 2B,A 3, a1A, a1B, a2C, b1, b2, CCK1 (CCKA), D1,D 3,D 4.4,
H1,H 2,M 1,M 2,M 3,M 4,M 5,N K 1, d2 (DOP), k (KOP), m (MOP),
5-HT1D, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT4e, 5-HT6, 5-HT7).
Notably, an agonistic effect on the k opioid receptor (21% of the
effect of the reference agonist U50488, EC50=1.2 nM, n=2), and
antagonistic effects on the d2 opioid receptor (76% residual activity
of the receptor in the presence of the reference agonist naltrindole
(IC50=0.37 nM, n=2) and the 5-HT1D receptor (62% residual
activity of the receptor in the presence of the reference agonist
methiothepin, IC50=1.1 mM, n=2) were observed. For other
GPCRs in the panel only weak responses in the single digit or low
double-digit percent range were found. These findings suggest
that, while lacking high affinity and selectivity to the primary
target hH4R, compound apparently 7 features a general
pharmacophore motif of aminergic GPCRs ligands.
Although the DOGS design approach is capable of suggesting
compounds of practical relevance, a potential improvement to
scoring would be to directly incorporate knowledge of a particular
pharmacophore, i.e. the requirement for a particular spatial
arrangement of potential interaction sites. This is only implicitly
considered by the current scoring scheme, which can lead to high
scores for designs exhibiting a spatial rearrangement of interaction
sites. We therefore consider combining the design algorithm with
scoring functions capable of taking 3D pharmacophore models
into account in future versions of the software.
In conclusion, we present a detailed description of a new
method for automated de novo design. The software had already
shown its potential to suggest selective and potent new compounds
together with a pursuable route to synthesize them in a previous
study [14]. Here, we provide in-depth insight into the algorithm
and analyze it theoretically. In addition, two prospective case
studies on automated design of bioactive compounds are
presented. An important feature of the algorithm is its minimal
demand for prior knowledge about the biological target. A single
reference compound is sufficient to have the algorithm come up
with suggestions for active compounds. This feature might be of
special merit for drug discovery addressing structurally unexplored
targets. However, despite these advances generating innovative
and patentable molecules with biological activity from scratch
remains a demanding goal. Current software solutions to this
problem are far away from being ‘click-and-harvest’ applications
guaranteed to produce readily exploitable results. De novo design
relies on the thoughtful intervention and support of a human
expert. Nevertheless, it can be a valuable source of inspiration and
new ideas for medicinal chemistry.
Supporting Information
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preprocessing reactions, unwanted substructures, description of
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